Eosinophilic Asthma Market to Show a Rise During the Study Period | Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline (GSK), Novartis, Sanofi, Regeneron Pharmaceutical, Avillion, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Conne

DelveInsight's "Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology as well as the Eosinophilic Asthma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Eosinophilic Asthma market report provides current treatment practices, emerging drugs, Eosinophilic Asthma market share of the individual therapies, and current and forecasted Eosinophilic Asthma market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Eosinophilic Asthma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Eosinophilic Asthma market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Here are some recent news and advancements in the eosinophilic asthma market:

### Recent News:
1. GSK's Nucala Approval in China: GSK's Nucala (mepolizumab) has been approved by the China National Medical Products Administration for severe eosinophilic asthma in adults and adolescents aged 12 years and above. This approval is supported by a Phase III trial conducted in China, which demonstrated significant reductions in exacerbations.
2. FDA Approval of Tezspire: The U.S. FDA approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma IN THE U.S. FOR SEVERE ASTHMA](https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-tezspire-tezepelumabekko-in-the-us-for-severe-asthma). Tezspire is notable for being the first biologic approved for severe asthma without phenotypic or biomarker limitations IN THE U.S. FOR SEVERE ASTHMA](https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-tezspire-tezepelumabekko-in-the-us-for-severe-asthma).
3. Market Growth Projections: The eosinophilic asthma market is expected to reach USD 10.26 billion by 2032, with a compound annual growth rate (CAGR) of 22%. This growth is driven by the increasing prevalence of severe asthma and advancements in biological treatments.

### Recent Advancements:
1. Dexpramipexole: A Phase II trial showed that oral doses of dexpramipexole significantly lowered eosinophil counts and improved lung function in patients with moderate-to-severe eosinophilic asthma. This drug offers an oral alternative to injectable treatments.
2. Vectura Group and Kinaset Therapeutics Agreement: The UK-based Vectura Group and Kinaset Therapeutics have entered into an agreement to develop and commercialize VR588, an inhaled pan-JAK inhibitor for the treatment of severe asthma.
3. GSK 294 Clinical Evaluation: GSK has dosed the first patient in a clinical trial to evaluate GSK 294 for the treatment of severe eosinophilic asthma (SEA).

These updates reflect ongoing efforts to improve treatment options and accessibility for patients with eosinophilic asthma. Is there a specific aspect of eosinophilic asthma treatment you're particularly interested in?

Eosinophilic Asthma Overview

Eosinophilic asthma is a subtype of asthma characterized by an elevated number of eosinophils, a type of white blood cell, in the airways. These eosinophils contribute to inflammation, which can worsen asthma symptoms. Below is an overview of eosinophilic asthma, including its causes, signs and symptoms, diagnosis, and treatment options:

Causes of Eosinophilic Asthma:
The exact cause of eosinophilic asthma is not fully understood, but it is thought to result from a combination of genetic factors and environmental triggers. Potential triggers include:
- Allergens (e.g., pollen, dust mites, mold, pet dander)
- Respiratory infections
- Air pollution
- Exposure to irritants, such as tobacco smoke

Signs and Symptoms of Eosinophilic Asthma:
The symptoms of eosinophilic asthma are similar to those of general asthma but may be more severe or persistent:
- Wheezing: A whistling sound when breathing, particularly when exhaling.
- Shortness of breath: Difficulty breathing, especially during physical activity or at night.
- Coughing: Often worse at night or early in the morning.
- Chest tightness: A sensation of pressure or discomfort in the chest.
- Exacerbated symptoms: Symptoms may worsen in response to triggers like allergens, cold air, or respiratory infections.
- Symptoms resistant to standard asthma treatments: Eosinophilic asthma may be suspected if asthma symptoms persist despite using typical asthma medications.

Diagnosis of Eosinophilic Asthma:
Diagnosis typically involves a combination of medical history, physical examination, and various diagnostic tests to assess eosinophil levels and lung function:
- Medical history and physical examination: A doctor will inquire about symptoms, triggers, and any past medical history.
- Lung function tests: Tests like spirometry and peak flow measurements help assess airflow and lung capacity.
- Fractional exhaled nitric oxide (FeNO) test: Measures nitric oxide levels in the breath, which are often elevated in eosinophilic asthma.
- Blood tests: These can measure eosinophil levels in the blood.
- Sputum eosinophil count: Analyzing mucus (sputum) can help determine eosinophil levels in the lungs.
- Imaging tests: Chest X-rays or CT scans may be used to rule out other conditions.

Treatment Options for Eosinophilic Asthma:
Management of eosinophilic asthma focuses on reducing inflammation and controlling symptoms. Treatment options include:
- Inhaled corticosteroids (ICS): These are the first-line treatment to reduce inflammation in the airways.
- Long-acting beta-agonists (LABAs): Often used in combination with ICS, LABAs help relax the muscles around the airways, making it easier to breathe.
- Biologic therapies: Targeted treatments aimed at inhibiting eosinophils or other inflammatory pathways. Key biologics include:
- Anti-interleukin-5 (IL-5) therapies: Medications like mepolizumab, reslizumab, and benralizumab specifically reduce eosinophil levels.
- Anti-immunoglobulin E (IgE) therapy: Omalizumab can be used for individuals with allergic asthma and elevated IgE levels.
- Oral corticosteroids: In severe cases or during asthma exacerbations, oral corticosteroids may be prescribed for short-term use to control inflammation.
- Trigger avoidance: Identifying and avoiding asthma triggers, such as allergens, irritants, or infections, is key to managing symptoms.
- Lifestyle modifications: Regular exercise, proper nutrition, and avoiding smoking can help manage asthma and improve overall lung health.

Managing Eosinophilic Asthma:
Treatment plans for eosinophilic asthma are often personalized, depending on the severity of symptoms, response to medications, and the presence of comorbidities. Ongoing monitoring and follow-up care with a healthcare provider are crucial to ensure optimal asthma control, minimize exacerbations, and adjust treatment as needed.

In conclusion, eosinophilic asthma requires a tailored approach to management, often involving a combination of pharmacological treatments and lifestyle adjustments to help control symptoms and improve quality of life for those affected.

Visit to know more about the Eosinophilic Asthma, treatment algorithms in different geographies, and patient journey contact to receive a sample @ https://www.delveinsight.com/report-store/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eosinophilic Asthma Market

The Eosinophilic Asthma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Eosinophilic Asthma market trends by analyzing the impact of current Eosinophilic Asthma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Eosinophilic Asthma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Eosinophilic Asthma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Eosinophilic Asthma market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eosinophilic Asthma Epidemiology

The Eosinophilic Asthma epidemiology section provides insights into the historical and current Eosinophilic Asthma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Eosinophilic Asthma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Explore more about the Eosinophilic Asthma Epidemiology at:
https://www.delveinsight.com/report-store/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eosinophilic Asthma Drugs Uptake

This section focuses on the rate of uptake of the potential Eosinophilic Asthma drugs recently launched in the Eosinophilic Asthma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Eosinophilic Asthma market uptake by drugs; patient uptake by therapies; and sales of each drug.

Eosinophilic Asthma Drugs Uptake helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs, and allows the comparison of the drugs on the basis of Eosinophilic Asthma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Request for a sample report to understand more about the Eosinophilic Asthma pipeline development activities at: https://www.delveinsight.com/report-store/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eosinophilic Asthma Therapeutics Assessment

Major pharma players such as Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline (GSK), Novartis, Sanofi, Regeneron Pharmaceutical, Avillion, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion, and others are working proactively in the Eosinophilic Asthma therapeutics market to develop novel therapies which will drive the Eosinophilic Asthma treatment market in the upcoming years.

Learn more about the emerging therapies & key companies at:
https://www.delveinsight.com/report-store/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Eosinophilic Asthma Report Key Insights

1. Eosinophilic Asthma Patient Population
2. Eosinophilic Asthma Market Size and Trends
3. Key Cross Competition in the Eosinophilic Asthma Market
4. Eosinophilic Asthma Market Dynamics (Key Drivers and Barriers)
5. Eosinophilic Asthma Market Opportunities
6. Eosinophilic Asthma Therapeutic Approaches
7. Eosinophilic Asthma Pipeline Analysis
8. Eosinophilic Asthma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Eosinophilic Asthma Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Eosinophilic Asthma Competitive Intelligence Analysis
4. Eosinophilic Asthma Market Overview at a Glance
5. Eosinophilic Asthma Disease Background and Overview
6. Eosinophilic Asthma Patient Journey
7. Eosinophilic Asthma Epidemiology and Patient Population
8. Eosinophilic Asthma Treatment Algorithm, Current Treatment, and Medical Practices
9. Eosinophilic Asthma Unmet Needs
10. Key Endpoints of Eosinophilic Asthma Treatment
11. Eosinophilic Asthma Marketed Products
12. Eosinophilic Asthma Emerging Therapies
13. Eosinophilic Asthma Seven Major Market Analysis
14. Attribute Analysis
15. Eosinophilic Asthma Market Outlook (7 major markets)
16. Eosinophilic Asthma Access and Reimbursement Overview
17. KOL Views on the Eosinophilic Asthma Market
18. Eosinophilic Asthma Market Drivers
19. Eosinophilic Asthma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Eosinophilic Asthma Market report here:
https://www.delveinsight.com/report-store/eosinophilic-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.